This randomized clinical trial investigates if tissue plasminogen activator (TPA) or perfluoropropane improve visual acuity or resolution of submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD) in eyes treated with ranibizumab.
This Viewpoint discusses significant revisions in the Declaration of Helsinki in response to changing ethical norms and technologies.
This Viewpoint discusses the 2024 revisions made to the Declaration of Helsinki as it continues to work toward ensuring research is subject to ethical standards…
This systematic review examines academic detailing programs targeted at improving prescribing behavior and describes program aspects associated with positive outcomes.
The findings could lead to a potential treatment for a common cause of blindness
This JAMA Special Communication presents the 2024 revision of the World Medical Association’s Declaration of Helsinki, a set of principles to guide the ethical treatment…
This JAMA issue focuses on important contemporary issues in ethics and medical research and is anchored by 2 Special Communications with their accompanying Viewpoints and…
This cohort study of men with prostate cancer examines the association of a health insurance payment incentive with adoption of active surveillance of low-risk cancers.
Learn about Glaucoma, Glaucoma signs and symptoms, and how to prevent blindness from Gluacoma
Wills Eye Resident Series : A patient presents with decreased vision after an injury , p. 62 medicare Q & A 2024 Reimbursement Update Wills…
To analyze endophthalmitis characteristics and risks following a 25-gauge vitrectomy or microincision vitrectomy surgery (MIVS).
